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Abstract: The aim of our study was to evaluate the relevance of donor-specific antibodies (DSA) as defined by solid-
phase single-antigen (SA) assays for predicting long-term graft survival after kidney transplantation. Sera from 132 
kidney transplant recipients were retrospectively tested before, 3, 6 and 12 months after transplantation. The incidence 
of rejection and graft survival was followed up for 7 years. We found 29 episodes of acute cellular rejection (CR), 21 
cases of antibody-mediated rejection (AMR) and 18 graft failures due to immunological reasons. Pre-transplant DSA 
and DSA three months after transplantation correlated with an increased rate of AMR and impaired graft function. After 
the fourth year, recipients with persistent DSA were at a higher risk of graft failure (p = 0.0317). Antibody specificity 
was prevailingly to HLA class I antigens (66.6% DSA, 75% non-DSA). During the first year after transplantation, the 
number of patients with non-DSA decreased (30.3% to 10.7%), while, due to de novo production of antibodies, the 
number of DSA positive patients remained constant.  
Conclusion: Detection of antibodies to HLA antigens using solid-phase assays, especially single-antigen bead 
technology before and three months after transplantation is predictive for increased incidence of antibody-mediated 
rejection and impaired long-term kidney graft survival. 
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Acute antibody-mediated rejection (AMR) is the main 
immunological cause of irreversible deterioration in 
graft function and impaired survival of the transplanted 
kidney.
1, 2
 The detection and definition of HLA donor-
specific antibodies (DSA) using solid-phase assays is 
now essential for the diagnosis of AMR. However, the 
role of pretransplant DSA and de novo-produced DSA 
(as defined by these techniques) in the assessment of 
long-term kidney graft survival is still uncertain. A 
number of studies have indicated worse graft survival 
in patients with pretransplant DSA and posttransplant 
de novo-produced DSA
3-6
, even though they are 
contradicted by other reports.
7, 8
 Intriguingly, two 
recent studies point out that non-donor-specific 
antibodies (non-DSA) might also have graft-damaging 
effects.
9, 10
 The clinical relevance of various technical 
modifications of the single-antigen Luminex assay, 
which involves the role played by complement-
activating vs. non-activating antibodies, is also under 
intense scrutiny.
11, 12
 Given the different and often 
contradictory data in the literature, the goal of our 
retrospective study was to evaluate the clinical 
relevance of DSA as well as non-DSA (as defined 
using the single-antigen bead technique) for the 




MATERIAL AND METHODS 
Our study included 132 kidney recipients who received 
kidneys from deceased donors in the Transplant centre  
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Female  50 (38%) 14 (28%) 8 (16%) 
First Transplanted  




PRA ≤ 10% 106 (81%) 25 (24%) 14 (13%) 
Retransplanted  




PRA ≤ 10%  7 (5%) 2 (29%) 4 (57%) 




Retransplanted   11 (8%)  2 (18%)   5 (45%) 
ABDR Mismatch  




≤ 4  98 (75%) 19 (19%) 14 (14%) 
Delayed graft 
function 
Yes 19 (14%) 4 (21%) 
NS 
 4 (21%) 
NS 
No 113 (86%) 25 (22%) 17 (15%) 
ATN3 
Yes 44 (33%) 12 (27%) 
NS 
 9 (20%) 
NS 
No 88 (67%) 17 (19%) 12 (14%) 
Induction Therapy 
Yes 29 (22%) 5 (17%)  
NS 
 4 (14%) 
NS 
No 103 (78%) 24 (23%)  17 (17%) 
Legend: 1ACR – cellular rejection, 2AMR – antibody-mediated rejection, 3ATN – acute tubular necrosis 
 
 
IKEM between 2004 and 2005. All recipients were 
followed up for graft function, patient and kidney graft 
survival for 7 years after transplantation. The research 
was approved by the ethics committee of the institute 
and written informed consent was obtained from all 
patients before their inclusion in the study. The 
demographic characteristics of our cohort are shown in 
Table 1.  
The detection and specification of HLA antibodies 
were performed before, 3, 6 and 12 months after 
transplantation. Patients with panel-reactive antibodies 
(PRA) > 50% before transplantation, as assessed using 
the complement-dependent lymphocytotoxic (CDC) 
assay, were treated with induction immunosuppressive 
therapy, including antithymocyte globulin (ATG) and 
corticosteroids. All kidney recipients had a negative 
CDC crossmatch test, performed with unseparated T 
and B cells (isolated from donor lymph nodes or the 
spleen) before transplantation. All pre- and post-
transplantation sera were analysed retrospectively 
using the Luminex technique. After transplantation, 
341 samples were analysed in total. The detection of 
HLA antibodies was performed using the LABScreen 
Mixed technique; positive sera from the LABScreen 
test were further tested for HLA specificity using single 
antigen (SA) beads (One Lambda Inc., Canoga Park, 
USA) according to the manufacturer’s instructions on a 
Luminex 200 System. A cut-off for positivity of 1000 
MFI and 2000 MFI was applied for class I and class II 
SA beads, respectively. Donor-specific antibodies were 
defined against HLA-A, -B and -DR antigens. 
Cellular (CR) and antibody-mediated rejection (AMR) 
were diagnosed in graft biopsies according to the 
updated Banff classification (2008)
13
; biopsies were 
performed at the time points of kidney graft function 
deterioration. AMR was defined by morphological 
evidence of acute tissue injury, immunofluorescent 
detection of diffuse C4d deposits in peritubular 
capillaries (>10%) and the simultaneous presence of 
DSA. The standard immunosuppressive protool after 
transplantation included calcineurin inhibitors, 
mycophenolate mofetil and corticosteroids. Statistical 
evaluation of data was performed using the Chi-square 
test, Fischer’s exact test and Log-Rank test. Kaplan-
Meier survival curves were drawn with GraphPad 




Incidence of rejection and graft loss 
During the 7-year follow-up, 29 cases of acute cellular 
rejection (ACR) and 21 antibody-mediated (AMR) 
rejections were diagnosed. Eighteen kidney recipients 
(13.6%) experienced ACR and 10 (7.6%) AMR, while 
11 developed AMR and ACR simultaneously (52% of 
all AMR episodes). AMR during the first year was 
observed in 17 (81%) cases; eight recipients developed 
AMR during the first month after transplantation and 7 
during the next 2 months after transplantation. A trend 
for higher occurrence of AMR with an increasing 
number of HLA mismatches was observed. Recipients 
with fully HLA-A, -B and -DR-matched grafts 
remained free of AMR, while 35% of those with 6 
HLA   mismatches  developed   AMR  (p = 0.049).  No  
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Preformed DSA2 21 (16%) 10 (48%) 0.0001 7 (33%) 0.0224 
  DSA class I only 14 (11%) 5 (36%) 0.0497 5 (36%) 0.0245 
  DSA class I (& class II) 17 (13%) 7 (41%) 0.0067 6 (35%) 0.0134 
  DSA class II only 4 (3%) 3 (75%)  0.0127 1 (25%) NS 
  DSA class II (& class I) 7 (5%) 5 (71%) 0.0011 2 (29%) NS 
  DSA class I and II 3 (2%) 2 (67%) NS 1 (33%) NS 
Preformed non DSA3 40 (30%) 4 (10%) NS 3 (8%) NS 
  Non-DSA class I only 30 (23%) 4 (13%) NS 3 (10%) NS 
  Non-DSA class II only 2 (1.5%) 0 NS 0 NS 
  Non-DSA class I & II 8 (6%) 0 NS 0 NS 
Legend: 1AMR – antibody-mediated rejection, 2DSA – donor-specific antibodies, 3Non-DSA – non-donor-specific antibodies 
 
 
influence of gender, PRA levels, induction 
immunosuppressive therapy or other factors on the 
development of cellular and antibody-mediated 
rejection was found (Table 1). AMR occurred more  
frequently after  retransplantation (p = 0.0179) and was 
associated with increased risk of graft failure: nine 
(43%) out of 21 recipients who experienced AMR lost 
their grafts, while 9 grafts (8%) failed  in  the  
remaining  111  recipients free of AMR (p = 0.0001).  
 
 
Pretransplant HLA antibodies 
Twenty-one (16%) recipients had preformed DSA 
before transplantation, while 40 (30%) had non-DSA. 
The majority of DSA specificities were against HLA 
class I antigens (66.7% class I; 14.3% class I & II); 
non-DSA were also more frequently specific to HLA 
class I antigens (75% class I, 20% I & II). The 
pretransplant presence of DSA significantly correlated 
with higher risk of AMR, both for class I- and class II-
specific antibodies (p < 0.0001) (Table 2), while non-
DSA were not associated with the occurrence of AMR.  
Concerning graft survival, DSA and especially DSA 
class I (also simultaneously with class II antibodies) 




Figure 1a. Kaplan-Meier curves of graft survival in kidney 
recipients with pretransplant DSA, non-DSA and without HLA 
antibodies. Increased risk of graft loss in pretransplant DSA-positive 
patients (p = 0.0330). 
failure (p = 0.0224) (Table 2 and Fig.1a). Interestingly, 
graft survival was similar between DSA-positive and 
DSA-negative cohorts, with graft failures in the DSA-
positive patients occurring more frequently only after 
the fourth year after transplantation. Comparison of 
individual specificities of DSA+ with DSA-negative 
recipients showed a trend of increased risk of graft 
failure in patients with DSA+ for class I (Log-Rank test 
p = 0.0106, Fig.1b). Pretransplant non-DSA did not 




Figure 1b. Kaplan-Meier curves of graft survival in DSA-positive 
and DSA-negative kidney recipients. Increased risk of graft failure 
in DSA class I positive recipients (p = 0.0106). 
 
 
Posttransplant HLA antibodies 
During the first year after transplantation, 15 recipients 
lost their preformed DSA (71.4% pretransplant DSA-
positive), and 21 recipients developed de novo DSA. 
Fifteen (71.4%) of those were pretransplant HLA 
antibody-negative, while 6 (28.6%) had pretransplant 
non-DSA. Six recipients (28.6%) had persistent 
pretransplant DSA at the end of the first year after 
transplantation. Conversely, non-DSA production 
decreased during the first year from 30.3% to 10.7%. 
During the first 3 months after transplantation, the 
presence of DSA correlated with a higher risk of AMR 
(p = 0.0074) (Table 3) and graft failure (compared with  
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Table 3. Donor and non-donor-specific antibodies after transplantation (3 months) and correlation with the incidence of antibody mediated 










DSA2 18 (14%) 6 (33%) 0.0074 6 (33%) 0.0299 
DSA class I only 13 (5 de novo) 3 (23%) NS 4 (31%) NS 
DSA class II only 3 (2 de novo) 2 (67%) NS 2 (67%) NS 
DSA class I and II 2 (1 de novo) 1 (50%) NS 0 NS 
Persistent DSA 10 (8%) 4 (40%) 0.0171 4 (40%) 0.0473 
Lost pretransplant DSA 11 (9%) 5 (45%) NS 3 (27%) NS 
De novo DSA 8 (6%) 2 (25%) NS 2 (25%) NS 
Non-DSA3 37 (30%) 8 (22%) 0.0551 5 (14%) NS 
Non-DSA class I only 20 (16%) 4 (20%) NS 4 (20%) NS 
Non-DSA class II only 5 (4%) 0 NS 0 NS 
Non-DSA class I and II 12 (9%) 4 (33%) NS 1 (8%) NS 
Legend: 1AMR - antibody mediated rejection, 2DSA – donor-specific antibodies, 3Non-DSA – non donor-specific antibodies 
 
 
DSA-negative recipients and those with non-DSA – 
Fig.2a). Interestingly, persistent DSA (pre- and post-
transplant) were related to the highest risk for 
development of AMR (p = 0.0171), while no 
correlation was found between de novo DSA and the 
incidence of AMR. Surprisingly, persistent DSA at 3 
months after transplantation were related to worse 
long-term (7 years) graft survival than de novo DSA at 
the same time point. De novo DSA played a role in 
graft survival during the first 4 years after 
transplantation (Fig.2b), but after the fourth year, 
recipients with pretransplant DSA were at a higher risk 
of graft failure. At 6 and 12 months after 
transplantation, the presence of antibodies (DSA and 
non-DSA) was not associated with AMR or graft 




As indicated above, testing for donor-specific 
antibodies is now essential for the diagnosis of AMR 
after organ transplantation.
14
 However, unresolved 
questions remain concerning the clinical relevance of 
antibodies (as defined using the SA technique) for 
predicting long-term allograft survival and the timing 
of posttransplant monitoring of antibodies. 
In line with previous reports, an increased risk of graft 
failure in transplant recipients who experienced AMR 
was observed.
15
 Retransplanted, high-risk kidney 
recipients and those with worse HLA matching with 
their respective donors were more prone to AMR. 
While all recipients included in the study were free of 
cytotoxic donor-specific antibodies before 
transplantation (CDC crossmatch negative), 
pretransplant DSA revealed retrospectively using the 
SA beads technique came up as a clear predictor for the 
development of AMR. This finding is in agreement 
with previous reports showing higher incidence of 
AMR in recipients with pretransplant DSA.
16-19
  
Concerning graft survival, a new intriguing finding of 
our study was that impaired survival in DSA-positive 
recipients became apparent only 4 years after 




Figure 2a. Kaplan-Meier curves of kidney recipients with HLA-
specific antibodies (DSA and non-DSA) and recipients without 
HLA antibodies. Increased risk of graft loss in DSA-positive 
patients (p = 0.0210). 
 
Figure 2b. Kaplan-Meier curves of graft survival in kidney 
recipients with persistent pretransplant DSA, de novo DSA and 
non-DSA detected 3 months after transplantation. Although de 
novo DSA played a main role in inferior graft survival during the 
first 4 years after transplantation, recipients with pretransplant DSA 
were at higher risk of graft failure after the fourth year (p = 0.0317). 
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allograft survival in recipients positive for DSA as 
defined using the SA technique; however, the follow-
up speculate that the relatively late graft failure in 
patients with pretransplant DSA might be due to the 
slow damaging effect exerted by (low-level) DSA (20) 
and/or by accommodation of the transplanted kidney to 
antibody injury.
21
 We found no correlation between 
non-DSA and the development of AMR
10
, even though 
almost one third (28%) of the cohort with non-DSA 
developed de novo DSA after transplantation. In 




As far as the relevance of the detection time point of 
antibodies, testing for DSA 3 months after 
transplantation is, in our estimation, important for 
predicting allograft outcomes. At 3 months, recipients 
with DSA had a higher risk for the development of 
AMR and worse long-term allograft survival. In our 
cohort, persistent DSA had a stronger impact on the 
incidence of AMR and graft survival in comparison 
with de novo DSA. Everly et al.
23
 suggest that the 
production of de novo DSA occurs more often during 
the first year after transplantation and that these 
antibodies are associated with graft failure, which is 
also in line with our findings.  
In conclusion, detection of antibodies to HLA antigens 
using SA bead technology before and three months 
after transplantation is predictive of impaired long-term 
graft survival. Patients with preformed and persisting 
DSA during the first three months after transplantation 





This study was supported by a project for the 
development of research, organization no. 00023001 




1. Colvin RB, Smith RN. Antibody-mediated organ-allograft 
rejection. Nat Rev Immunol. 2005;5: 807-817. 
2. Farkash EA, Colvin RB. Diagnostic challenges in chronic 
antibody-mediated rejection Nat Rev Nephrol. 2012;8: 
255-257. 
3. Loupy A, Suberbielle-Boissel C, Hill GS, Lefaucheur C, 
Anglicheau D, Zuber J, Martinez F, Thervet E, Méjean A, 
Charron D, Duong van Huyen JP, Bruneval P, Legendre 
C, Nochy D. Outcome of subclinical antibody-mediated 
rejection in kidney transplant recipients with preformed 
donor-specific antibodies. Am J Transplant. 2009;9: 
2561-2570. 
4. Otten HG, Verhaar MC, Borst HP, Hené RJ, van Zuilen 
AD. Pretransplant donor-specific HLA class-I and -II 
antibodies are associated with an increased risk for kidney 
graft failure. Am J Transplant. 2012;12:1618-1623. 
5. Lefaucheur C1, Loupy A, Hill GS, Andrade J, Nochy D, 
Antoine C, Gautreau C, Charron D, Glotz D, Suberbielle-
Boissel C. Preexisting donor-specific HLA antibodies 
predict outcome in kidney transplantation. J Am Soc 
Nephrol. 2010;21:1398-1406. 
6. Wiebe C, Gibson IW, Blydt-Hansen TD, Karpinski M, Ho 
J, Storsley LJ, Goldberg A, Birk PE, Rush DN, Nickerson 
PW. Evolution and clinical pathologic correlations of de 
novo donor-specific HLA antibody post kidney transplant. 
Am J Transplant. 2012;12:1157-1167. 
7. Amico P, Hönger G, Mayr M, Steiger J, Hopfer H, 
Schaub S. Clinical relevance of pretransplant donor-
specific HLA antibodies detected by single-antigen flow-
beads. Transplantation. 2009;87 1681-1688. 
8. Süsal C, Ovens J, Mahmoud K, Döhler B, Scherer S, 
Ruhenstroth A, Tran TH, Heinold A, Opelz G. No 
association of kidney graft loss with human leukocyte 
antigen antibodies detected exclusively by sensitive 
Luminex single-antigen testing: a Collaborative 
Transplant Study report. Transplantation. 2011;91:883-
887. 
9. Süsal C, Wettstein D, Döhler B, Morath C, Ruhenstroth 
A, Scherer S, Tran TH, Gombos P, Schemmer P, Wagner 
E, Fehr T, Živčić-Ćosić S, Balen S, Weimer R, Slavcev 
A, Bösmüller C, Norman DJ, Zeier M, Opelz G; 
Collaborative Transplant Study Report. Association of 
Kidney Graft Loss With De Novo Produced Donor-
Specific and Non-Donor-Specific HLA Antibodies 
Detected by Single Antigen Testing. Transplantation. 
2015;99:1976-1980. 
10. Richter R, Süsal C, Köhler S, Qidan S, Schödel A, 
Holschuh L, Brzoska M, Asbe-Vollkopf A, Büttner S, 
Betz C, Herrmann E, Gauer S, Seifried E, Geiger H, Seidl 
C, Hauser I. Pretransplant human leukocyte antigen 
antibodies detected by single-antigen bead assay are a risk 
factor for long-term kidney graft loss even in absence of 
donor-specific antibodies. Transplant International. 
2016;29:988-998. 
11. Lefaucheur C, Viglietti D, Bentlejewski C, Duong van 
Huyen JP, Vernerey D, Aubert O, Verine J, Jouven X, 
Legendre C, Glotz D, Loupy A, Zeevi A. IgG Donor-
Specific Anti-Human HLA Antibody Subclasses and 
Kidney Allograft Antibody-Mediated Injury. J Am Soc 
Nephrol. 2016;27:293-304. 
12. Guidicelli G, Guerville F, Lepreux S, Wiebe C, Thaunat 
O, Dubois V, et al. Non-Complement-Binding De Novo 
Donor-Specific Anti-HLA Antibodies and Kidney 
Allograft Survival. J Am Soc Nephrol. 2016;27:615-625. 
13. Solez K, Colvin RB, Racusen LC, Haas M, Sis B, Mengel 
M, Halloran PF, Baldwin W, Banfi G, Collins AB, Cosio 
F, David DS, Drachenberg C, Einecke G, Fogo AB, 
Gibson IW, Glotz D, Iskandar SS, Kraus E, Lerut E, 
Mannon RB, Mihatsch M, Nankivell BJ, Nickeleit V, 
Papadimitriou JC, Randhawa P, Regele H, Renaudin K, 
Roberts I, Seron D, Smith RN, Valente M. Banff 07 
classification of renal allograft pathology: updates and 
future directions. Am J Transplant. 2008;8:753-760. 
14. Eckels DD, Stehlik J, Kfoury AG. The detection and role 
of circulating antibodies in rejection. Curr Opin Organ 
Transplant. 2013;18:589-594. 
15. Gosset C, Lefaucheur C, Glotz D. New insights in 
antibody-mediated rejection. Curr Opin Nephrol 
Hypertens. 2014;23:597-604. 
16. Lefaucheur C, Loupy A, Hill GS, Andrade J, Nochy D, 
Antoine C, Gautreau C, Charron D, Glotz D, Suberbielle-
Boissel C. Preexisting donor-specific HLA antibodies 
predict outcome in kidney transplantation. J Am Soc 
Nephrol. 2010;21:1398-1406. 
17. Willicombe M, Brookes P, Santos-Nunez E, Galliford J, 
Ballow A, Mclean A, Roufosse C, Cook HT, Dorling A, 
Warrens AN, Cairns T, Taube D. Outcome of patients 
with preformed donor-specific antibodies following 
alemtuzumab induction and tacrolimus monotherapy. Am 
J Transplant. 2011;11:470-477. 
18. Caro-Oleas JL, González-Escribano MF, Gentil-Govantes 
MÁ, Acevedo MJ, González-Roncero FM, Blanco GB, 
Núñez-Roldán A.. Clinical relevance of anti-HLA donor-
specific antibodies detected by Luminex assay in the 
development of rejection after renal transplantation. 
Transplantation. 2012;94:338-44. 
 
Svobodova E, Slavcev A 
DOI: 10.33602/mebm.3.1.3 
Molecular and Experimental Biology in Medicine, 2020, 3(1): 17-22 
 
19. Worthington JE, Martin S, Al-Husseini DM, Dyer PA, 
Johnson RW. Posttransplantation production of donor 
HLA-specific antibodies as a predictor of renal transplant 
outcome. Transplantation. 2003;75:1034-1040. 
20. Einecke G, Sis B, Reeve J, Mengel M, Campbell PM, 
Hidalgo LG, Kaplan B, Halloran PF. Antibody-mediated 
microcirculation injury is the major cause of late kidney 
transplant failure. Am J Transplant. 2009;9:2520-2531. 
21. Cai J, Terasaki PI. Humoral theory of transplantation: 


































































22. Loupy A, Lefaucheur C, Vernerey D, Prugger C, Duong 
van Huyen JP, Mooney N, Suberbielle C, Frémeaux-
Bacchi V, Méjean A, Desgrandchamps F, Anglicheau D, 
Nochy D, Charron D, Empana JP, Delahousse M, 
Legendre C, Glotz D, Hill GS, Zeevi A, Jouven X. 
Complement-binding anti-HLA antibodies and kidney-
allograft survival. N Engl J Med. 2013;1215-1226. 
23. Everly MJ, Rebellato LM, Haisch CE, Ozawa M, Parker 
K, Briley KP, Catrou PG, Bolin P, Kendrick WT, 
Kendrick SA, Harland RC, Terasaki PI. Incidence and 
impact of de novo donor-specific alloantibody in primary 
renal allografts. Transplantation. 2013;95:410-417. 
